ERBB2 and non-small cell lung carcinoma: Despite the ATLAS study investigated the clinical activity of currently available HER2-targeted TKIs for heterogeneous HER2 missense mutations in NSCLC, along with valuable evidence from in silico structural analysis, several limitations must be noted.